Caribou Biosciences expands its clinical programme for CB-010 with FDA nod to initiate clinical trial in lupus, Verve Therapeutics pauses ongoing...
In this update, we highlight recent news on Poseida Therapeutics' fully allogeneic CAR-T candidate for multiple myeloma (P-BCMA-ALLO1), Intellia's and...
AvenCell Therapeutics recently announced that the first patient has been dosed in a Phase 1A study with its lead product candidate AVC-201. This novel...
HuidaGene Therapeutics recently announced that the FDA has granted Orphan Drug Designation to its CRISPR-based therapeutic candidate, HG302. The...
Ascidian Therapeutics announced this week that the FDA has cleared its investigational new drug (IND) application and granted fast track designation...
Fate Therapeutics announced this week that enrolment is underway for a Phase 1 trial of FT-825/OMO-8250 in advanced HER2-expressing solid tumours.
As 2023 draws to a close, we look back on some of the major clinical highlights from the year gone by.
Caribou Biosciences gets closer to Phase 3 with its gene-edited cell therapy candidate for large B-cell lymphoma, and Editas Medicine reports positive...
